21:24:39 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriLäkemedel & Handel
NattoPharma är ett norskt bolag verksamma inom utveckling av läkemedel. Idag innehas störst fokus på utveckling av diverse kosttillskott. Ledande varumärken säljs huvudsakligen via MenaQ7, ett vitamintillskott av K2 karaktär. En stor del av verksamheten fokuserar på forskning och utveckling inom arbetsområdet, vilket sker via separata dotterbolag. Bolaget etablerades 2004 och har sitt huvudkontor i Oslo.

Kalender

2022-01-26 Bokslutskommuniké 2021
2021-07-14 Kvartalsrapport 2021-Q2
2021-06-30 Årsstämma 2021
2021-05-27 Ordinarie utdelning NATTO 0.00 NOK
2021-02-17 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-07-15 Kvartalsrapport 2020-Q2
2020-06-22 Ordinarie utdelning NATTO 0.00 NOK
2020-06-19 Årsstämma 2020
2020-05-06 Kvartalsrapport 2020-Q1
2020-02-19 Bokslutskommuniké 2019
2019-11-13 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-31 Ordinarie utdelning NATTO 0.00 NOK
2019-05-29 Årsstämma 2019
2019-04-30 Kvartalsrapport 2019-Q1
2019-02-13 Bokslutskommuniké 2018
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning NATTO 0.00 NOK
2018-05-30 Årsstämma 2018
2018-02-08 Bokslutskommuniké 2017
2017-11-24 Extra Bolagsstämma 2017
2017-08-16 Kvartalsrapport 2017-Q2
2017-05-16 Ordinarie utdelning NATTO 0.00 NOK
2017-05-15 Årsstämma 2017
2017-05-15 Kapitalmarknadsdag 2017
2017-05-15 Kvartalsrapport 2017-Q1
2017-02-08 Bokslutskommuniké 2016
2016-11-16 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-20 Kvartalsrapport 2016-Q1
2016-05-20 Årsstämma 2016
2016-02-26 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2014-11-26 Kvartalsrapport 2014-Q3
2014-08-27 Kvartalsrapport 2014-Q2
2014-05-27 Kvartalsrapport 2014-Q1
2014-02-17 Bokslutskommuniké 2013
2013-11-26 Kvartalsrapport 2013-Q3
2013-08-27 Kvartalsrapport 2013-Q2
2013-05-22 Kvartalsrapport 2013-Q1
2013-02-28 Bokslutskommuniké 2012
2012-11-15 Kvartalsrapport 2012-Q3
2012-08-21 Kvartalsrapport 2012-Q2
2012-05-16 Kvartalsrapport 2012-Q1
2012-02-28 Bokslutskommuniké 2011
2012-02-13 Extra Bolagsstämma 2012
2011-11-17 Kvartalsrapport 2011-Q3
2011-10-31 Extra Bolagsstämma 2011
2011-08-18 Kvartalsrapport 2011-Q2
2011-05-19 Kvartalsrapport 2011-Q1
2011-02-25 Bokslutskommuniké 2010
2021-03-02 07:36:15
Oslo, 2 March 2021: Reference is made to the stock exchange announcement on 15
February 2021 regarding Compagnie des Levures Lesaffre's ("Lesaffre" or the
"Offeror") intention to launch a voluntary cash offer (the "Offer") for all
outstanding shares of NattoPharma ASA ("NattoPharma" or the "Company"), and the
stock exchange announcement on 25 February 2021 in which certain terms and
conditions of the Offer was amended. In the 25 February 2021 announcement the
offer price was increased to NOK 35 per share, and the condition of a minimum
acceptance level of 90% of the issued and outstanding share capital of
NattoPharma (on a fully diluted basis) was reduced to 66.67%.

As set out in the 25 February 2021 announcement, the Offeror had as of 25
February 2021 received irrevocable pre-commitments, which together with the
agreements entered into with the option holders in the Company providing for an
unconditional obligation to exercise the options and tender the option shares to
the Offeror, comprised 12,777,054 shares representing 60.74% of the total share
capital of NattoPharma, on a fully diluted basis excluding treasury shares.

Following the 25 February 2021 announcement, the Company has been informed by
Lesaffre that Lesaffre has acquired 350,359  shares in NattoPharma and received
371,118 additional irrevocable pre-commitments and that none of these purchases
were made at a price in excess of the Offer Price of NOK 35 per share.

Reference is further made to the mandatory notifications of trade by certain
primary insiders in NattoPharma on 1 March 2021, in which it was announced that
TG Montgomery AS has conditionally agreed to purchase 386,360 shares in
NattoPharma, and Pro AS has acquired 160,000 shares in NattoPharma (collectively
the "Additional Shares"). Both the shares conditionally to be purchased by TG
Montgomery AS and the shares acquired by Pro AS  are covered by such parties'
irrevocable pre-commitments with Lesaffre.

Based on this, Lesaffre has in respect of the contemplated Offer received
commitments (including its own shares in NattoPharma) for 14,044,891 shares
representing 66.76% of the total share capital of NattoPharma, on a fully
diluted basis excluding treasury shares, and the 66.67% acceptance level
conditions is therefore expected to be satisfied upon completion of the Offer.

The Company has been informed that TG Montgomery AS and Pro AS have acquired the
Additional Shares on their own initiative without any prior understanding with
Lesaffre and that the Offer Price of NOK 35 pr share will not be amended as a
result of the acquisition of the Additional Shares by TG Montogmery AS and Pro
AS.

For further information, please contact:
NattoPharma ASA
Att: Kjetil Ramsøy
Telephone: +47 906 12 943
Email: kjetil.ramsoy@nattopharma.com

This information is subject to the disclosure requirements of NattoPharma
pursuant to section 5 -12 of the Norwegian Securities Trading Act.